ICUI · NASDAQ · STOCK
ICU Medical (ICUI) Stock Analysis
$160.29
52W $113.37 – $192.85
55/100
$4.01B
133.6
0.76
Is ICUI Bullish or Bearish?
Mixed.
Innellis AI committee rates ICU Medical, Inc. (ICUI) Watch with a composite score of 55/100
, based on 5 analysts with 40% agreement.
Last updated October 10, 2026.
What Would Change This View
- Upgrade to Buy
- Requires a committee score of 60.0 — +4.83 from today. Applies on the first day at or above the line; upgrades are never dampened.
- Downgrade to Reduce
- Requires the score to fall below 40.0 — -15.17 from today. The band boundary is 45.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.
Executive Summary
The committee is genuinely divided. Macro Analyst sees a compelling case. Portfolio Manager remains cautious — sector concentration is already high (hhi 2796.97). This disagreement is itself the signal — the setup is not clean in either direction.
Bull & Bear Case
Bull Case
- 4 consecutive earnings beats -- consistent execution — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- MACD histogram positive -- bullish momentum — Technical
Bear Case
- P/E of 132.2 is expensive by classic value standards — Value
- ROE of only 1.4% -- cheap may mean cheap for a reason — Value
- Revenue declining -9.0% YoY -- this is not a growth story right now — Growth
Both cases are generated from quantitative data signals, not qualitative or
forward-looking judgement. They summarise what the numbers say today.
Price History (6M)
AI Investment Committee
Committee Consensus
As of October 10, 2026
Overall Committee Score
55/100
Agreement
40%
Analysts
5
Conviction
Contested
Sector Rank
Top 64%
of 192 Healthcare peers
Value Analyst
bearish
35
/ 100 · Moderate confidence
Multiples don't clear a genuine value bar here, or cheapness looks justified by weak fundamentals
− P/E of 132.2 is expensive by classic value standards
Growth Analyst
bullish
60
/ 100 · High confidence
Strong, accelerating growth with consistent execution
+ 4 consecutive earnings beats -- consistent execution
− Revenue declining -9.0% YoY -- this is not a growth story right now
Technical Analyst
neutral
58
/ 100 · High confidence
Mixed or range-bound price action
+ MACD histogram positive -- bullish momentum
Macro Analyst
bullish
65
/ 100 · Low confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
News Analyst
neutral
58
/ 100 · Low confidence
News flow is mixed or quiet -- no strong signal either way right now
Portfolio Manager
bearish
30
/ 100 · Moderate confidence
The existing book itself argues for caution here, independent of how good this specific stock looks
− Sector concentration is already high (HHI 2796.97)
Investment Thesis Evolution
Committee score moved marginally from 55.2 to 55.2.
- New bearish signals: 1 appeared.
- Bearish pressure eased: 1 signal(s) disappeared.
Analyst-level changes:
- Value Analyst: +1 bearish signal(s).
Comparing 2026-10-09 to 2026-10-10 (1 day apart).
Technical Analysis
RSI (14)
51.1
Neutral
MACD Histogram
0.194
Bullish Momentum
Trend Direction
Sideways
Weekly: Uptrend
Market Structure
Mixed
Support
$137.93
Resistance
$189.38
Bollinger %B
0.56
Inside Bands
Price vs Moving Averages
EMA 9
$159.40
Above
EMA 21
$160.97
Below
EMA 50
$162.21
Below
EMA 200
$150.69
Above
Fundamental Analysis
Valuation
65
Growth
94
Profitability
13
Financial Health
98
Cash Flow
70
Valuation
P/E Ratio
133.6×
P/B Ratio
1.86×
PEG Ratio
0.01
Dividend Yield
0.00%
52W High
$192.85
52W Low
$113.37
Quality & Growth
ROE
3.5%
ROA
1.8%
Gross Margin
3756.5%
Operating Margin
503.7%
Revenue Growth YoY
—
Debt / Equity
0.59
AI Fundamental Assessment
P/E ratio of 133.6 (rich relative to a 15-40x range); Price-to-book of 1.9x; PEG ratio of 0.0 (under 1.0 suggests growth is undervalued relative to price); Return on equity of 0.0%; Return on assets of 0.0%; Net margin of 1.4%; Gross margin of 37.6%; Current ratio of 2.43 (healthy short-term liquidity); Debt-to-equity of 0.59; Free cash flow per share is positive (6.11); Most recent quarter beat estimates by 21.4%; 4 consecutive earnings beats; EPS growth accelerating (+3.1% -> +20.3% QoQ); Analyst estimates rising over recent quarters
Get the Full ICUI Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →